About
TRiCBIO provides human organoid-based research services for drug discovery, efficacy, safety, mechanism, immune-context, and custom model development. It works with biopharma, CRO, and research collaboration projects, with studies run from Nanjing and project support from Shanghai and Philadelphia.
Services
Organoid target discovery & functional genomics
Discover genetic dependencies through organoid library screening and validate targets with tumor, microenvironment, and treatment-response readouts.
Target validation & mechanism studies
Test candidate targets in human organoids through disease phenotypes, molecular changes, and treatment response.
Mechanism & biomarker studies
Link tissue, functional, and molecular results to treatment response and prioritize biomarker candidates for validation.
Custom model development
Develop model and assay plans for specialized tissues, rare diseases, or complex co-cultures based on available samples and endpoints.
Organoid efficacy screening
Compare single agents and combinations in tumor PDOs and selected human organoid models to identify dose responses and differences across models.
Immuno-oncology
Evaluate immune activation and tumor-cell killing in PDO 2.0 / ALI models or immune co-cultures with tissue imaging and functional assays.
Antibody, multispecific & T-cell engager (TCE) studies
Compare tumor-cell killing, immune activation, and cytokine changes for antibody, multispecific, and TCE candidates in human tumor organoids and immune co-cultures.
ADC research
Combine target expression, spatial distribution, cytotoxicity, and bystander-effect readouts in organoid studies matched to ADC candidates.
7 more services
- Safety & toxicology
- Multi-organ safety in human organoids
- Drug delivery & barrier permeability
- Mechanism & biomarkers
- Human intestinal organoid IBD-like inflammation model
- Tailored ADPKD organoid cyst-phenotype studies
- BBB co-culture & permeability methods
Capabilities
- Assays and studies
- Antibodies
- ADCs
- Flow cytometry
- Toxicology
- Small molecules
- Library screening
18 more
- Functional genomics
- Target validation
- Mechanism studies
- Morphology
- Histology
- Immunofluorescence
- Cytokine assays
- Viability
- Apoptosis
- Gene expression/qPCR
- Barrier permeability
- Transport assays
- Injury marker analysis
- Genetic-library screening
- Treatment-response studies
- Functional assays
- H&E
- IHC
- Scale and capacity
- ALI · 96-well adaptable
- 24-well · 96-well adaptable
- Therapeutic areas
- Oncology
- Immuno-oncology
- Kidney injury
- Gastrointestinal disease
- Inflammatory bowel disease
- ADPKD
9 more
- Blood-brain barrier
- Head and neck cancer
- Mesenchymal tumors
- Drug discovery
- Drug development
- Safety
- Inflammation
- Inherited kidney disease
- Neurovascular-barrier research
Instruments and platforms
- Flow cytometry
- H&E
- IHC
- IF
- Microscopy equipment
Modalities and species
- Modalities
- Small molecule
- Antibody
- Bispecific
- ADC
- Species and models
- Human tumor organoids
- Human kidney organoids
- Normal lung organoids
- Human intestinal organoids
- Adjacent non-tumor liver organoids
- H9 human embryonic stem cell (hESC)-derived kidney organoids
11 more
- HUVEC–astrocyte co-culture
- Patient-derived tumor organoids (PDO 1.0, PDO 2.0 / ALI)
- IBD-like intestinal organoid model
- ADPKD hPSC-derived kidney organoids
- Human organoids
- PDO 1.0
- PDO 2.0
- ALI tumor-immune organoids
- Tumor PDOs
- Normal-tissue organoids
- hPSC-derived kidney organoids
Industries served
- Biopharma
- CRO
- Biotech
- Academic research
Company
- Type
- CRDMO
- Quality
- Model QC (morphology, markers and functional readouts) · batch QC (model and assay summary, model/batch QC, original images or data, and study report) · model quality assessed through morpholog · methods, results and data sources docume
Locations
- Based in
- Nanjing, China
- Sites
- Shanghai, China
- Philadelphia, US
- Serves
- China, global, global clients
Contacts
- Phone
- +86 400 880 3160